Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyer
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.1.1 Increasing adoption of protein-based drugs over non-protein based drugs
4.1.2. Reduction in overall time and cost for drug discovery
4.1.3. Growth in funding for protein engineering
4.2 Restraints
4.2.1 High Costs
4.2.2 High maintenance of tools & instruments used in protein engineering
4.3 Opportunities
4.3.1 Significant growth opportunities in emerging economies
4.3.2 Protein therapy as an alternative to gene therapy
4.4 Challenges
4.4.1 Need of qualified researchers or skilled staff in protein engineering
Chapter 6 Protein Engineering Market - By Product Type
6.1 Modified Proteins
6.2 Modified Enzymes
6.3 Insulin
6.4 Monoclonal Antibodies
6.5 Blood Factors
6.6 Tissue Plasminogen Activator
6.7 Fusion Proteins
Chapter 7 Protein Engineering Market - By Technology
7.1 Introduction
7.2 Irrational protein design
7.3 Rational protein design
Chapter 8 Protein Engineering Market - By End User
8.1 Biotechnology Companies
8.2 Pharmaceutical Companies
8.3 Academic Institutions
8.4 Contract Research Organizations (CROs)
Chapter 9 Protein Engineering Market - By Geography
9.1. Introduction
9.2. Americas
9.2.1. The U.S.
9.2.2 Canada
9.2.3 Mexico
9.2.4 Brazil
9.2.5 Argentina
9.2.6 Others
9.3 Europe
9.3.1 U.K.
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Others
9.4 Asia Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Others
9.5 The Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10 Competitive Landscape
11.1 Market Share Analysis
11.2. Strategies Adopted by Top Companie
11.3 Agreements, Partnerships, Collaborations, Expansions and Acquisitions
Chapter 12 Company profiles
12.1 Agilent Technologies
12.1.1. Company Overview
12.1.2 Financial Performance
12.1.3 Product Benchmarking
12.1.4 Developmental Strategies
12.2 Bruker Corporation
12.3 GE Healthcare
12.4 Waters Corporation
12.5 Sigma-Aldrich Corporation
12.6 GenScript USA Inc
12.7 Danaher Corporation
12.8 Bio-Rad Laboratories
12.9 Perkinelmer, Inc.
12.10 Thermo Fisher Scientific
12.11 General electric company
12.12 AB SCIEX
12.13 NOVARTIS AG
12.14 GLAXOSMITHKLINE INC
12.15 ELI LILLY AND COMPANY
Chapter 13 Market Insights
13.1 Insights of Industry Experts
13.2 Analyst Opinions
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
14.3 Discussion Guide
14.4 Available Customizations
14.5 Related Reports
